Alto Neuroscience (NYSE:ANRO) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Alto Neuroscience (NYSE:ANRO) announced its quarterly earnings results on Thursday. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09, Zacks reports.

Alto Neuroscience Stock Up 0.6 %

Shares of Alto Neuroscience stock opened at $2.71 on Friday. Alto Neuroscience has a 12-month low of $2.58 and a 12-month high of $18.35. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The company’s 50-day moving average price is $3.63 and its 200-day moving average price is $6.15.

Analyst Ratings Changes

Separately, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research report on Friday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $16.75.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.